Filgrastim Market by Drug Type, Indication, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030

List of Tables

The global filgrastim market was valued at $ 562.50 million in 2020 and is projected to reach $ 745.90 million by 2030 registering a CAGR of 2.80% from 2021 to 2030.

Filgrastim is a drug that is used to increase the production of granulocytes (a type of white blood cell) in patients who are receiving treatment that causes low white blood cell counts. Filgrastim is used to prevent infection and neutropenic (low white blood cells) fevers caused by chemotherapy. Filgrastim is a support medication used in this therapy. Filgrastim injection is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to bone marrow. Furthermore, filgrastim is in a class of medications called colony-stimulating factors. It aids the body's production of neutrophils. On the other hand, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting.

Factors such as increase in prevalence of various diseases and surge in geriatric population, drive the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. Conversely, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.

The global filgrastim market segmented on the basis of drug type, distribution channel, indication and region. On the basis of drug type, it is further classified into biologic and biosimilar. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Based on indication, it is categorized into chemotherapy induced netropenia, chronic neutropenia and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global filgrastim market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps understand the drug types of filgrastim market used across the globe.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Drug Type

Biologic
Biosimilar

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Indication

Chemotherapy induced Netropenia
Chronic Neutropenia
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories
Amgen
Apotex
Cadila Pharmaceuticals
Dr. Reddy's Laboratories "
Kirin Holding (Kyowa Kirin)
Novartis
Pfizer
Teva Pharmaceutical Industries Ltd
Toksoz Group (Arven)

Product Code: A03303

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
- 1.3.1.List of key players profiled in the report
1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
- 3.5.1.Drivers
  - 3.5.1.1.Surge in geriatric population
  - 3.5.1.2.Rise in demand for biosimilars in the treatment of neutropenia
  - 3.5.1.3.Pharmaceutical companies are shifting toward biosimilar drug development
- 3.5.2.Restraints
  - 3.5.2.1.Complexities in manufacturing of biosimilar
  - 3.5.2.2.Increase in use of pegfilgrastim biologic
- 3.5.3.Opportunities
  - 3.5.3.1.Increase in player-adopted strategies
  - 3.5.3.2.Increase in awareness related to filgrastim
- 3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on the filgrastim market

CHAPTER 4:FILGRASTIM MARKET, BY DRUG TYPE

4.1.Overview
- 4.1.1.Market size and forecast
4.2.Biologic
- 4.2.1.Key market trends, growth factors, and opportunities
- 4.2.2.Market size and forecast, by region
  - 4.2.2.1.Market size and forecast for biologic by distribution channel
- 4.2.3.Market analysis, by country
4.3.Biosimilar
- 4.3.1.Key market trends, growth factors, and opportunities
- 4.3.2.Market size and forecast
  - 4.3.2.1.Market size and forecast for biosimilar by distribution channel
- 4.3.3.Market analysis, by country

CHAPTER 5:FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview
- 5.1.1.Market size and forecast
5.2.Hospital pharmacies
- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country
5.3.Retail pharmacies
- 5.3.1.Market size and forecast
- 5.3.2.Market analysis, by country
5.4.Online pharmacies
- 5.4.1.Market size and forecast
- 5.4.2.Market analysis, by country

CHAPTER 6:FILGRASTIM MARKET, BY INDICATION

6.1.Overview
- 6.1.1.Market size and forecast
6.2.Chemotherapy induced Netropenia
- 6.2.1.Market size and forecast, by region
- 6.2.2.Market analysis, by country
6.3.Chronic neutropenia
- 6.3.1.Market size and forecast, by region
- 6.3.2.Market analysis, by country
6.4.Others
- 6.4.1.Market size and forecast, by region
- 6.4.2.Market analysis, by country

CHAPTER 7:FILGRASTIM MARKET, BY REGION

7.1.Overview
- 7.1.1.Market size and forecast
7.2.North America
- 7.2.1.Key market trends, growth factors, and opportunities
- 7.2.2.Market size and forecast, by country
  - 7.2.2.1.U.S. filgrastim market
  - 7.2.2.2.U.S. filgrastim market, by drug type
  - 7.2.2.3.U.S. filgrastim market, by distribution channel
  - 7.2.2.4.U.S. filgrastim market, by indication
  - 7.2.2.5.Canada filgrastim market
  - 7.2.2.6.Canada filgrastim market, by drug type
  - 7.2.2.7.Canada filgrastim market, by distribution channel
  - 7.2.2.8.Canada filgrastim market, by indication
  - 7.2.2.9.Mexico filgrastim market
  - 7.2.2.10.Mexico filgrastim market, by drug type
  - 7.2.2.11.Mexico filgrastim market, by distribution channel
  - 7.2.2.12.Mexico filgrastim market, by indication
- 7.2.3.North America market size and forecast, by drug type
- 7.2.4.North America market size and forecast, by distribution channel
- 7.2.5.North America market size and forecast, by indication
7.3.Europe
- 7.3.1.Key market trends, growth factors, and opportunities
- 7.3.2.Market size and forecast, by country
  - 7.3.2.1.Germany filgrastim market
  - 7.3.2.2.Germany filgrastim market, by drug type
  - 7.3.2.3.Germany filgrastim market, by distribution channel
  - 7.3.2.4.Germany filgrastim market, by indication
  - 7.3.2.5.France filgrastim market
  - 7.3.2.6.France filgrastim market, by drug type
  - 7.3.2.7.France filgrastim market, by distribution channel
  - 7.3.2.8.France filgrastim market, by indication
  - 7.3.2.9.UK filgrastim market
  - 7.3.2.10.UK filgrastim market, by drug type
  - 7.3.2.11.UK filgrastim market, by distribution channel
  - 7.3.2.12.UK filgrastim market, by indication
  - 7.3.2.13.Italy filgrastim market
  - 7.3.2.14.Italy filgrastim market, by drug type
  - 7.3.2.15.Italy filgrastim market, by distribution channel
  - 7.3.2.16.Italy filgrastim market, by indication
  - 7.3.2.17.Spain filgrastim market
  - 7.3.2.18.Spain filgrastim market, by drug type
  - 7.3.2.19.Spain filgrastim market, by distribution channel
  - 7.3.2.20.Spain filgrastim market, by indication
  - 7.3.2.21.Rest of Europe filgrastim market
  - 7.3.2.22.Rest of Europe filgrastim market, by drug type
  - 7.3.2.23.Rest of Europe Filgrastim market, by distribution channel
  - 7.3.2.24.Rest of Europe Filgrastim market, by indication
- 7.3.3.Europe market size and forecast, by drug type
- 7.3.4.Europe market size and forecast, by distribution channel
- 7.3.5.Europe market size and forecast, by indication
7.4.Asia-Pacific
- 7.4.1.Key market trends, growth factors, and opportunities
- 7.4.2.Market size and forecast, by country
  - 7.4.2.1.Japan Filgrastim market
  - 7.4.2.2.Japan Filgrastim market, by drug type
  - 7.4.2.3.Japan Filgrastim market, by distribution channel
  - 7.4.2.4.Japan Filgrastim market, by indication
  - 7.4.2.5.China Filgrastim market
  - 7.4.2.6.China Filgrastim market, by drug type
  - 7.4.2.7.China filgrastim market, by distribution channel
  - 7.4.2.8.China filgrastim market, by indication
  - 7.4.2.9.Australia filgrastim market
  - 7.4.2.10.Australia filgrastim market, by drug type
  - 7.4.2.11.Australia filgrastim market, by distribution channel
  - 7.4.2.12.Australia filgrastim market, by indication
  - 7.4.2.13.India filgrastim market
  - 7.4.2.14.India filgrastim market, by drug type
  - 7.4.2.15.India filgrastim market, by distribution channel
  - 7.4.2.16.India filgrastim market, by indication
  - 7.4.2.17.South Korea filgrastim market
  - 7.4.2.18.South Korea filgrastim market, by drug type
  - 7.4.2.19.South Korea filgrastim market, by distribution channel
  - 7.4.2.20.South Korea filgrastim market, by indication
  - 7.4.2.21.Rest of Asia-Pacific filgrastim market
  - 7.4.2.22.Rest of Asia-Pacific filgrastim market, by drug type
  - 7.4.2.23.Rest of Asia-Pacific filgrastim market, by distribution channel
  - 7.4.2.24.Rest of Asia-Pacific filgrastim market, by indication
- 7.4.3.Asia-Pacific market size and forecast, by drug type
- 7.4.4.Asia-Pacific market size and forecast, by distribution channel
- 7.4.5.Asia-Pacific market size and forecast, by indication
7.5.LAMEA
- 7.5.1.Key market trends, growth factors, and opportunities
- 7.5.2.Market size and forecast, by country
  - 7.5.2.1.Brazil filgrastim market
  - 7.5.2.2.Brazil filgrastim market, by drug type
  - 7.5.2.3.Brazil filgrastim market, by distribution channel
  - 7.5.2.4.Brazil filgrastim market, by indication
  - 7.5.2.5.Saudi Arabia filgrastim market
  - 7.5.2.6.Saudi Arabia filgrastim market, by drug type
  - 7.5.2.7.Saudi Arabia filgrastim market, by distribution channel
  - 7.5.2.8.Saudi Arabia filgrastim market, by indication
  - 7.5.2.9.South Africa filgrastim market
  - 7.5.2.10.South Africa filgrastim market, by drug type
  - 7.5.2.11.South Africa filgrastim market, by distribution channel
  - 7.5.2.12.South Africa filgrastim market, by indication
  - 7.5.2.13.Rest of LAMEA filgrastim market
  - 7.5.2.14.Rest of LAMEA filgrastim market, by drug type
  - 7.5.2.15.Rest of LAMEA filgrastim market, by distribution channel
  - 7.5.2.16.Rest of LAMEA filgrastim market, by indication
- 7.5.3.LAMEA market size and forecast, by drug type
- 7.5.4.LAMEA market size and forecast, by distribution channel
- 7.5.5.LAMEA market size and forecast, by indication

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES
- 8.1.1.Company overview
- 8.1.2.Company snapshot
- 8.1.3.Operating business segments
- 8.1.4.Product portfolio
- 8.1.5.Business performance
8.2.AMGEN INC.
- 8.2.1.Company overview
- 8.2.2.Company snapshot
- 8.2.3.Operating business segments
- 8.2.4.Product portfolio
- 8.2.5.Business performance
8.3.APOTEX INC.
- 8.3.1.Company overview
- 8.3.2.Company snapshot
- 8.3.3.Operating business segments
- 8.3.4.Product portfolio
8.4.DR. REDDY'S LABORATORIES LIMITED
- 8.4.1.Company overview
- 8.4.2.Company snapshot
- 8.4.3.Operating business segments
- 8.4.4.Product portfolio
- 8.4.5.Business performance
8.5.KIRIN HOLDINGS
- 8.5.1.Company overview
- 8.5.2.Company snapshot
- 8.5.3.Operating business segments
- 8.5.4.Product portfolio
- 8.5.5.Business performance
8.6.NOVARTIS AG
- 8.6.1.Company overview
- 8.6.2.Company snapshot
- 8.6.3.Operating business segments
- 8.6.4.Novartis offers the following products:
- 8.6.5.Business performance
- 8.6.6.Key strategic moves and developments
8.7.PFIZER INC.
- 8.7.1.Company overview
- 8.7.2.Company snapshot
- 8.7.3.Operating business segments
- 8.7.4.Product portfolio
- 8.7.5.Business performance
8.8.TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 8.8.1.Company overview
- 8.8.2.Company snapshot
- 8.8.3.Operating business segments
- 8.8.4.Product portfolio
- 8.8.5.Business performance
8.9.TOKSOZ GROUP.
- 8.9.1.Company overview
- 8.9.2.Company snapshot
- 8.9.3.Operating business segments
- 8.9.4.Product portfolio
8.10.ZYDUS CADILLA
- 8.10.1.Company overview
- 8.10.2.Company snapshot
- 8.10.3.Operating business segments
- 8.10.4.Product portfolio
- 8.10.5.Business performance